MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions

Shares :

0
(0)
Mind Cure Health Inc. Logo (CNW Group/Mind Cure Health Inc.)

LUCID’s technology platform unites music, AI and research in neuroscience to create personalized digital music therapy managed in real-time by therapists based on patient feedback

VANCOUVER, BC, April 21, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce a partnership with LUCID Inc. (“LUCID”). LUCID’s mission is to help people optimize their mental wellness through music, and they will be designing custom psychedelic music experiences for iSTRYM.

After announcing its data partnership with Speak Ai last week, MINDCURE continues to integrate world-class technologies into and create proprietary experiences within iSTRYM, its psychedelics digital therapeutics platform. LUCID’s platform is a key differentiator for iSTRYM as therapists and patients seek out scientifically validated tools to enhance the effectiveness of psychedelic-assisted therapies. It will enable the therapist to alter the music within a therapy session based on real-time feedback and data collected from the patient, all within iSTRYM.

“We look forward to working with MINDCURE’s team and bringing our expertise to psychedelic-assisted therapies,” said Zach McMahon, LUCID CEO and Co-Founder. “Our team will be researching and taking into consideration the therapeutic targets and mechanisms of action associated with each psychedelic while leveraging our machine learning systems to optimize the music experiences in iSTRYM for personalization and efficacy.”

Music has been shown to be effective as a stress and anxiety management tool and also has shown efficacy for diverse outcomes, including chronic and acute pain.1Listening to music evokes a wide range of emotions,and because of this, music listening has been a component of several psychological interventions in the area of anxiety and depression, such as post-traumatic stress disorder.3,With this integration, therapists will have access to music designed for psychedelic-assisted therapies and specific psychedelic compounds that is changing in real-time based on patient feedback, AI and collected data to deepen or alter the experience.

__________________________
Choi et al.. 2018; Vaajoki et al., 2010; Shabanloei et al., 2010; Good et al., 2005; Smyth et al., 2018; Chai et al., 2020;
Jangsirikul et al., 2017
2 Bandelow, B., & Michaelis, S. (2015). Epidemiology of anxiety disorders in the 21st century. Dialogues in Clinical
Neuroscience, 17(3), 327–335.
3 Bensimon, M., Amir, D., & Wolf, Y. (2012). A pendulum between trauma and life: Group music therapy with post-
traumatized soldiers. The Arts in Psychotherapy, 39, 223–233. doi:10.1016/j. aip.2012.03.005
4 Panteleeva, Y., Ceschi, G., Glowinski, D., Courvoisier, D. S., & Grandjean, D. (2018). Music for anxiety? Meta-analysis of 
anxiety reduction in non-clinical samples. Psychology of Music, 46(4), 473–487. 

“We are building first-of-its-kind functionality by pairing AI-driven music scapes with a therapist’s art of directing the experience for patients in psychedelic-assisted therapy sessions,” said Kelsey Ramsden, MINDCURE President and CEO.“Integrating LUCID will further enhance iSTRYM’s capabilities and its potential as the validated backbone of the roll-out of psychedelic therapy and trusted wingman for therapists and patients who want a digital therapeutic partner that allows for quantified medicine with personalization at scale.”

“Music interventions have well-indicated positive effects on anxiety and depression, and are frequently used alongside psychedelic therapies. We recently concluded a randomized controlled trial of LUCID’s personalized music technology and found it to be more effective than comparator technologies in alleviating symptoms of anxiety in adults diagnosed with moderate trait anxiety. We plan to continue building this body of evidence in diverse use-cases, including as an adjunct to psychedelic therapy,” said Dr. Frank Russo, Professor of Psychology and Director of the SMART Lab at Ryerson University.

LUCID’s core technology is based on the use of quantitative measurement of mood and physiological state, coupled with robust personalization techniques made possible by machine learning, to optimize music interventions for specific cognitive outcomes. Using psychometric and biometric measurement to determine the user’s current mental state and machine learning agents, LUCID systems adaptively predict the optimal musical sequence to help an individual reach their desired state.

These tools are further leveraged to intelligently compose, produce, and remix music with the highest possible therapeutic potential for precise outcomes. In addition to the music, LUCID employs a novel method to seamlessly integrate auditory beat stimulation (including binaural beats) within the fabric of the music for additional benefit.

About LUCID Inc. (LUCID):

LUCID‘s mission is to transform the mental health industry by unlocking the potential of music therapy through innovative AI technology. LUCID emphasizes non-invasive and accessible tools to help people with their mental health, by providing evidence-based and scientifically-validated personalized music therapies based on real-time mood assessment. With patented technology and a clinical research pipeline, LUCID is committed to scientifically validating music as medicine.

LUCID’s partners and collaborators include Mitacs, the Ontario Brain Institute, Ontario Centres of Excellence, Next Canada, MaRS, and Ryerson University. LUCID’s advisors include Dr. Rébecca Kleinberger from MIT Media Lab,  CAMH’s Chief of General and Health Systems Psychiatry Dr. Farooq Naeem, Ryerson SMART Lab’s Dr. Frank Russo, and Dr. Sageev Oore of Dalhousie’s Vector Institute of AI. 

The Company also announces it has granted a total of 610,000 stock options to certain employees or consultants pursuant to the terms the Company’s incentive stock option plan (“Plan”). The stock options are exercisable at a price of $0.60per share and subject to the terms of the Plan.

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.


Sign up for MORE news updates !


This article is written and published by The Cannabis Stock


Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Click on a star to rate this article !

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.


Shares :